Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary
PCI. The hypothesis is, that higher concentration of abciximab i.c. leads to improved
epicardial flow, perfusion, reduction of no-reflow, reduction in infarct size and
subsequently better outcome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Leipzig
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments